Ryan & Maniskas, LLP (
) is investigating potential claims against the board of directors of Trubion Pharmaceuticals, Inc. ("Trubion" or the "Company") (NASDAQ:TRBN) concerning possible breaches of fiduciary duty and other violations of law related to the Company’s entry into an agreement to be acquired by Emergent BioSolutions Inc. (“Emergent”) in a transaction valued at approximately $96.8 million.
Our investigation concerns possible breaches of fiduciary duty and other violations of law related to approval of the transaction by Company’s board of directors; in particular, whether the Company undertook a fair process to obtain fair consideration for all shareholders of Trubion. For more information regarding our investigation, please contact Ryan & Maniskas, LLP (Richard A. Maniskas, Esquire) toll-free at (877) 316-3218 or by email at
Under the proposed agreement, each share of Trubion common stock will be converted into the right to receive $1.365 per share in cash and 0.1641 shares of Emergent stock. In addition, Trubion shareholders will receive one contingent value right ("CVR") per share, which will entitle the holder to receive cash payments based upon the achievement of certain milestones. The total potential aggregate value of the CVRs is $38.7 million over a three year period.
If you own shares of Trubion and would like to learn more about these claims or if you wish to discuss these matters and have any questions concerning this announcement or your rights, contact Richard A. Maniskas, Esquire toll-free at (877) 316-3218 or to sign up online, visit:
. You may also email Mr. Maniskas at
. For more information about class action cases in general, please visit our website:
Ryan & Maniskas, LLP is a national shareholder litigation firm. Ryan and Maniskas, LLP is devoted to protecting the interests of individual and institutional investors in shareholder actions in state and federal courts nationwide.